公开(公告)号：US20180230087A1

公开(公告)日：2018-08-16

申请号：US15860095

申请日：2018-01-02

Applicant: The Board of Regents of the University of Texas System

Inventor： Jung-Mo AHN ,  Ganesh RAJ

IPC: C07C235/56 ,  A61K31/167 ,  C07D493/10 ,  C07C237/44 ,  C07C279/08 ,  C07C237/06

CPC classification number: C07C235/56 ,  A61K31/167 ,  C07C237/06 ,  C07C237/44 ,  C07C279/08 ,  C07D493/10

Abstract: The present invention includes bis- and tris-benzamide compounds that block AR signaling and have anticancer activity. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.

公开(公告)号：US20160130217A1

公开(公告)日：2016-05-12

申请号：US14932480

申请日：2015-11-04

Applicant: The Board of Regents of the University of Texas System

Inventor： Jung-Mo AHN ,  Ganesh RAJ

IPC: C07C235/56 ,  C07D493/10

CPC classification number: C07C235/56 ,  A61K31/167 ,  C07C237/06 ,  C07C237/44 ,  C07C279/08 ,  C07D493/10

Abstract: The present invention includes bis- and tris-benzamide compounds that block AR signaling and have anticancer activity. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.

公开(公告)号：US20220306584A1

公开(公告)日：2022-09-29

申请号：US17596816

申请日：2020-06-20

Applicant: The Board of Regents of the University of Texas System

Inventor： Jer-Tsong HSIEH ,  Jung-Mo AHN ,  Zhi-Ping LIU

IPC: C07D215/26 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  A61P35/00

Abstract: The present disclosure provides a new series of 8-hydroxyquinoline derivatives/analogs that are potent KDM4 inhibitors with high activity and selectivity against KDM4 enzymes. Also disclosed are the pharmaceutical compositions comprising such 8-hydroxyquinoline-based potent KDM4 inhibitors, or a pharmaceutically acceptable salt thereof, and method of use thereof, for treating cancer and neoplastic diseases and the like.

公开(公告)号：US20160031803A1

公开(公告)日：2016-02-04

申请号：US14792072

申请日：2015-07-06

Applicant: The Board of Regents of the University of Texas System

Inventor： Jung-Mo AHN ,  Ganesh RAJ

IPC: C07C237/44

CPC classification number: C07C237/44 ,  A61B2017/00274 ,  A61F7/10 ,  A61K31/167 ,  A61K31/24 ,  A61K31/365 ,  A61K45/06 ,  A61N5/10 ,  C07C235/56 ,  C07C237/04 ,  A61K2300/00

Abstract: The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.

公开(公告)号：US20140323568A1

公开(公告)日：2014-10-30

申请号：US14259644

申请日：2014-04-23

Applicant: The Board of Regents of the University of Texas System

Inventor： Jung-Mo AHN ,  Ganesh RAJ

IPC: A61K31/167 ,  C07C237/04 ,  A61F7/10 ,  A61K45/06 ,  A61N5/10 ,  C07C235/56 ,  A61K31/24

CPC classification number: C07C237/44 ,  A61B2017/00274 ,  A61F7/10 ,  A61K31/167 ,  A61K31/24 ,  A61K31/365 ,  A61K45/06 ,  A61N5/10 ,  C07C235/56 ,  C07C237/04 ,  A61K2300/00

Abstract: The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.

Abstract translation: 本发明包括阻断AR信号并具有抗前列腺癌活性的双 - 和三 - 苯甲酰胺化合物。 也提供了这些化合物的用途和含有它们的药物组合物。